On October 30, 2024, Cognition presented a pre-specified analysis of data from the Phase 2 SHINE study (NCT03507790) of CT1812 in participants with mild-to-moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. An archived recording of that event is available below.
Download the presentation (PDF)